Panno speaks on recent changes, page-37

Blane, I agree that one person on this thread is making statements that have little to no foundation in the evidence that has been published to-date.

When considering any link between TT-034 results and BB-101/3, we should also note that HBV (not HCV) assists in the transduction of AAV's in liver cells through the HBV protein X. So, if low nucleus transduction was a problem for TT-034 (and I am not suggesting it was), it does not follow that it will be for BB-101/3. My point is that good pre-clinical data for HBV may be sufficient to combat any possible negative data from the TT-034 trial. My only concern is that, as far as I can remember, the BB-101 dosing levels that have shown good results are at AAV levels that other trials have shown to produce an immune response. This is another reason why I think that there will be a change to a more modern vector.